REGENXBIO Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed February 27, 2024. This annual filing does not provide standalone fourth-quarter results. REGENXBIO is a clinical-stage gene-therapy company whose revenue comes from licenses and royalties, not sales of its own products.
Financial performance and position
| Metric | FY2023 / year-end | Prior comparable period |
|---|---|---|
| Revenue | $90.2 million | $112.7 million in 2022 |
| Operating expenses | $358.4 million | $375.6 million in 2022 |
| Operating loss | $268.1 million | $262.9 million in 2022 |
| Net loss | $263.5 million; $6.02 per diluted share | $280.3 million; $6.50 per diluted share in 2022 |
| Cash used in operating activities | $218.4 million | $207.5 million in 2022 |
| Cash, cash equivalents and marketable securities | $314.1 million | $565.2 million at year-end 2022 |
| Total assets / total liabilities | $574.0 million / $262.2 million | $833.3 million / $317.1 million at year-end 2022 |
- Zolgensma royalties were $85.3 million, about 95% of total revenue, versus $101.9 million in 2022. The company attributed the decline partly to an 11% reported decrease in Zolgensma sales and established markets increasingly treating incident patients.
- Year-end cash and marketable securities included $34.5 million of cash and equivalents and $279.6 million of marketable securities. Current assets were $335.0 million and current liabilities $130.3 million.
- The royalty-sale liability to HCR was $94.1 million, down from $137.6 million; operating lease liabilities were $89.3 million. The filing reports no off-balance-sheet arrangements.
- Management said available cash and marketable securities were expected to fund operations and commitments for at least 12 months from the filing date, while also stating that significant additional capital will be needed to achieve business objectives.
Material changes and notable items
- Revenue fell 20% year over year, mainly due to lower Zolgensma royalties. The $370 million AbbVie upfront license payment was recognized in 2021, not 2023.
- Operating expenses declined 5%; research and development expense decreased to $232.3 million from $242.5 million. AbbVie assumed the majority of ABBV-RGX-314 development expenses beginning in 2023, and REGENXBIO recorded $74.2 million of net AbbVie cost reimbursements against R&D expense.
- Net loss narrowed by $16.8 million. Lower HCR-related interest expense and higher investment income helped offset the operating loss. 2022 results included $7.5 million of settlement income; 2023 included a $2.2 million investment gain tied to Corlieve/uniQure milestone proceeds.
- In November 2023, the company prioritized ABBV-RGX-314, RGX-202 and RGX-121, reduced its workforce by approximately 15%, and began seeking strategic alternatives for RGX-111, RGX-181 and RGX-381. It recorded $3.7 million in restructuring charges and expected related cash payments to finish by Q4 2024.
Outlook, programs and principal risks
- ABBV-RGX-314: ATMOSPHERE and ASCENT pivotal wet-AMD trials were enrolling; global regulatory submissions were expected from late 2025 through the first half of 2026. In January 2024, the company reported Phase II suprachoroidal data showing an 80% reduction in annualized injection rate at the highest dose and 50% of patients injection-free. These are interim company-reported findings, not approval evidence.
- RGX-202: The company expected a pivotal-dose determination in mid-2024 and initial strength and functional data, plus initiation of a pivotal trial, in the second half of 2024. February 2024 interim biomarker data were reported after year-end.
- RGX-121: In February 2024, the company reported that the pivotal CAMPSIITE phase achieved its primary endpoint, with an 86% median reduction in CSF D2S6 at 16 weeks. It planned a BLA submission in the second half of 2024, subject to completing remaining activities and regulatory requirements.
- No product revenue or profitability guidance was provided. Management expects continuing losses and significant R&D and administrative spending; timing and amount of future licensing, milestone and royalty revenue are uncertain.
- Key risks include clinical safety and efficacy, regulatory acceptance of surrogate endpoints and accelerated-approval pathways, manufacturing scale and quality, competition, reliance on collaborators and licensees, intellectual-property disputes, and concentrated revenue. In January 2024, a court granted Sarepta summary judgment dismissing REGENXBIO’s patent case; the company appealed, and the outcome remains uncertain.
- The financial statements received an unqualified audit opinion, and the auditor also opined that internal control over financial reporting was effective. Royalty revenue recognition was identified as a critical audit matter.
Important facts for investors to verify
- Current cash runway assumptions, expected burn after restructuring, and whether additional financing will be required.
- Novartis Zolgensma sales, royalty receipts, and the remaining HCR repayment schedule and cap terms.
- Progress and full safety, efficacy and durability data from ABBV-RGX-314, RGX-202 and RGX-121 trials, including regulatory agreement on endpoints and BLA timing.
- Execution and realized savings from the workforce reduction, and outcomes of strategic alternatives for deprioritized programs.
- Concentration of revenue in Novartis, collectability of the fully reserved $4.6 million Abeona receivable, and the status of the Sarepta appeal.